283 In the index

Dasatinib DASA

An FDA-approved cancer drug for a type of leukemia, also being studied combined with a plant compound to clear out old, damaged cells linked to aging. Early human studies of that anti-aging use show it can reduce markers of cellular aging, but this remains experimental and separate from its approved cancer use.

Also known as Sprycel, Dasatinib anhydrous, Dasatinib (anhydrous), BMS 354825, dasatinibum, anh. dasatinib, anhydrous dasatinib

Effects Longevity

Routes Oral

Legal status Prescription drug

WADA Not listed

3D Molecular Structure of C₂₂H₂₆ClN₇O₂S

Drag to rotate · scroll to zoom

Chemistry

Formula: C22H26ClN7O2S
Molar mass: 488.0
CAS: 302962-49-8
PubChem CID: 3062316
IUPAC name: N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
InChIKey: ZBNZXTGUTAYRHI-UHFFFAOYSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 100 mg/day (oncology indication)

Reported range 70-140 mg/day (oncology); much lower intermittent doses (e.g., 100 mg for 2 days) studied experimentally as a senolytic

Route Oral

Frequency Once or twice daily (oncology); occasional intermittent dosing in senolytic research

Duration Chronic (oncology, as prescribed) or short intermittent courses (experimental senolytic use)

FDA-approved for leukemia (Sprycel); its use as a senolytic (often paired with quercetin) is experimental and not an approved indication.

Where this comes from FDA prescribing information; early-phase senolytic clinical trials

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.